Table 1.

Safety variables recorded and samples collected during the in-life phase

Variables	Study daysa
Clinical observations	General observations twice daily Cageside observations once daily Observations 1 h ± 15 min postdose Detailed observations (Days 7, 10, 13, 21, 28, 34, 41, 44, 47, 55, 62, 69, 75, 78, 81 and 89) 1 h ± 15 min postdose (on dosing days)
Body weight	Days 1, 8, 11, 14, 21, 28, 35, 42, 45, 48, 55, 62, 69, 76, 79, 82, 88 and 89
Food consumption	Daily
Physical and neurological examinations	Days 20, 34, 54, 68 and 88
Injection sites scoring	Days of injection (predose and 7 to 8 h postdose) and at 24, 48, and 72 h (±1 h) following each injection
Ophthalmologic examination	Day 88
Electrocardiographic examination	1 h ± 15 min postdose on Days 20 and 88
Buccal mucosal bleed times	Days 20 and 88
Clinical pathology	Days 21, 55 and 89
Bioanalytical collection	Dose cycle 1: On days 1 and 14, samples were collected predose and 1 and 5 h postdose On days 6, 8 and 11, samples were collected 1 and 5 h postdose Dose cycle 3: On days 69 and 82, samples were collected predose and 1 and 5 h postdose On days 74, 76 and 79, samples were collected 1 and 5 h postdose

^aDosing phase length was 88 days and necropsies were performed at study termination at Day 89